NeuroInsights, LLC

Specific findings from the Neurotechnology Industry 2007 Report include:

- Brain-related illnesses afflict more than two billion people worldwide
- The worldwide economic burden of brain-related illness has reached more than $2 trillion per year; more than $1 trillion in the U.S. alone
- 2006 venture capital investment in neurotechnology rose 7.5% to $1.6 billion
- Neurotech industry revenues rose 10% in 2006 to $120.5 billion; this includes neuropharmaceutical revenues of $101 billion, neurodevice revenues of $4.5 billion, neurodiagnostic revenues of $15 billion (report breaks down by submarket)
- Compounds and devices in clinical trials by company, mechanism of action, and stage of development
- Profiles of 500 public & private neurotech including neuropharmaceutical, neurodevice, neurodiagnostic companies
- Worldwide government research, private funding and public investment trends
- Analysis of the 10 most active neurotech venture capital firms, including investments by market segment
- Public neurotech investment trends, including a neurotech tracking index highlighting 30 public neurotech companies - Extensive discussion of the specific technological, demographic, regulatory, and IP trends driving neurotech
- Up-to-date market data and detailed competitive intelligence for over 15 major markets including Alzheimer’s, addiction, anxiety, depression, epilepsy, mild cognitive impairment, obesity, pain, Parkinson’s, schizophrenia, sensory disorders, sleep disorders, stroke and more

"The Neurotech Industry Report provides the first comprehensive view of drugs, devices and diagnostics for the brain and nervous system.

It is a must read for any investor or executive in the industry." Roger Quy, PhD, General Partner, Technology Partners

"A penetrating analysis of the complex industry that is bringing us new treatments for the brain and the mind.” Samuel Barondes, PhD, Director, Center for Neurobiology and Psychiatry, UCSF

"Neurotech companies are addressing the largest and fastest growing unmet medical market and the potential for high return investment has never been more compelling.” Mark Cochran, CEO, Blanchett Rockefeller Neuroscience Institute and Managing Director, NeuroVentures Capital

“Finally a complete view of companies, technologies and global trends driving neurotechnology. The Neurotechnology Industry Report fills a big gap that traditional CNS market and investment reports miss." Global Healthcare Group, Major Investment Bank